1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
Nitric oxide and its possible implication in ME/CFS (Part 1 of 2)
Andrew Gladman explores the current and historic hypotheses relating to nitric oxide problems in ME/CFS. Part 1 of a 2-part series puts nitric oxide under the microscope and explores what it is, what it does and why it is so frequently discussed in the world of ME/CFS. Part 1 focuses...
Discuss the article on the Forums.

Retrovirus Conference in Prague, April 29-May 4, 2010

Discussion in 'XMRV Research and Replication Studies' started by parvofighter, Mar 3, 2010.

  1. parvofighter

    parvofighter Senior Member

    Messages:
    436
    Likes:
    99
    Canada
    Another Retrovirus conference: with more of the hot XMRV researchers attending this conference in the EU. Might one of our Czech Republic or EU members attend?

    Prague 2010 Centennial Retrovirus Conference: Ap 29-May 04, 2010
    Institute of Molecular Genetics, Prague, Czech Republic

    From: http://www.crm2010.org/programme/provisional-programme.html

    Presenters include:
    Paul Jolicoeur (Clinic. Res. Inst., Montreal, Canada) Dr Jolicoeur is doing a Canadian study on ME/CFS and XMRV. Might he be reporting on the results??: Presentation: Action @ the cell surface
    John Coffin (Tufts, MA): Presentation: Retrovirus Evolution
    Jonathan Stoye (NIMR, London, UK): Cellular Defenses
    Francis W. Ruscetti (NIH, MD): Roles of Innate and Adapted Defenses in Infections by Retroviruses
    Stephen P. Goff (Columbia U, NY): Summary observations

    Registration info: http://www.crm2010.org/registration.html
    All participants are kindly recommended to register via the Online Registration Form.

    REGISTRATION FEES
    Early registration
    (before 8 March 2010)
    Late registration(between 9 March 2010 & 14 April 2010)
    Delegate
    480 EUR
    580 EUR
    Student*
    250 EUR
    300 EUR
    Accompanying person
    40 EUR
    45 EUR
    * Letter of confirmation signed by Head of Department is to be faxed/emailed to Meeting Secretariat for Student fee application.

    My Note:
    Interestingly, the conference program is almost meticulous in NOT mentioning XMRV. So no guarantee how much focus there might be on XMRV... Then again, some of the key XMRV researchers are tantalizingly there. And this is not a severely expensive conference, especially for students. Is this something the forum members might sponsor, for one of our EU members to attend and report back? Might the WPI or CAA or IACFSME or ESME send a delegate?
  2. Cort

    Cort Phoenix Rising Founder

    Messages:
    7,025
    Likes:
    435
    Raleigh, NC
    Parvo is on fire! Ruscetti, Joliceur - Andrea W. said - 'wait until April' but why no mention of CFS or XMRV.........All the descriptions seem pretty general, though. hmmmm
  3. parvofighter

    parvofighter Senior Member

    Messages:
    436
    Likes:
    99
    Canada
    Cross-functional topics?

    Not so sure about the fire... :In bed: I'm just being a scribe.
    Keep in mind too, that of the over 40 speakers, they only mention AIDS once, much less HIV. My guess is they're either trying to be very cross-functional across HIV/HTLV/XMRV/ERV's... or trying to keep unpublished (?or about-to-be-published?) XMRV topics out of the media. Again, hmmm?!
  4. Kati

    Kati Patient in training

    Messages:
    1,884
    Likes:
    1,051
    If Dr Jolicoeur is going over there, then it must be because he got something to say??? Please say something nice!
    (For those that don't know, he's a canadian scientist). Maybe they will broadcast some information online?
  5. Alesh

    Alesh Senior Member

    Messages:
    176
    Likes:
    0
    Czech Republic, EU
    Accidentally, I work part time in the same campus but not in the Institute of Molecular Genetics, where this conference will take place. I know that they are planning to have a special section on XMRV at least according to this member of the organizing committee:

    http://www.img.cas.cz/public/skupiny/Hejnar.html
  6. Frickly

    Frickly Senior Member

    Messages:
    1,046
    Likes:
    34
    Texas
    Alesh, Can you peak in and tell us what happens? :D:D:D
  7. shrewsbury

    shrewsbury member

    Messages:
    1,540
    Likes:
    54
    Alesh -THanks for the inside scoop. I hope that you'll be able to attend some of the conference. How exciting.

    I wonder why Mikovits isn't presenting.

    I just sent an email asking about broadcasting & posting vids+transcripts. The CROI did such a great job of it - hope these guys do too.

    The emails of the organizing committee, in case anyone else wants to do the same, are:

    rene.daniel@jefferson.edu; anna.skalka@fccc.edu; hejnar@img.cas.cz; svoboda@img.cas.cz; takac@img.cas.cz; info@crm2010.org
  8. shrewsbury

    shrewsbury member

    Messages:
    1,540
    Likes:
    54
    I just heard back from them. I do hope someone can make it to the conference!

  9. Frickly

    Frickly Senior Member

    Messages:
    1,046
    Likes:
    34
    Texas
    I soooo want to go to Prague! :D
  10. Navid

    Navid Senior Member

    Messages:
    409
    Likes:
    58
    Prague in the Springtime...so lovely!!!!

    oooh me too...it's such a beautiful city.

    but that's the catch 22 w/this darn disease we're too physically weak and tired to go to these conferences where we would be visible as the faces and voices of CFID's.

    hopefully someone can attend and report back to us.

    thank god for our computers!!!!!:D:
  11. Rita

    Rita Senior Member

    Messages:
    235
    Likes:
    5
  12. natasa778

    natasa778 Senior Member

    Messages:
    1,403
    Likes:
    1,195
    London UK
    Thank you Rita!

    Is it me or is there not a single XMRV presentation?? Only a German prostate poster session...
  13. Michelle

    Michelle Decennial ME/CFS patient

    Messages:
    104
    Likes:
    10
    Portland, OR
    XMRV presentations at Prague Retrovirus conference including Mikovits

    As I haven't seen it posted yet, I thought I'd go ahead and do it, especially since I usually just lurk/read the forum voraciously but don't have much energy to actually participate.

    (Abstract removed. Sorry - Good Digging! - but we've been asked by the WPI not to display Dr. Mikovits abstract on the site because of worries about prepublication dispersal of it. Yes, the abstract is available for public viewing on the conference website but researchers at the conferences understand that public discussion of it is a no no and they refrain from that. We, on the other hand, are almost like a kind of media outlet - so we have to be careful that we're not dispersing into into the general public - where its not supposed to be. That's my understanding anyway.)
    --------------------------------------------

    P53

    'Prevalence of XMRV in prostate cancer and chronic fatigue syndrome
    patients in Germany'
    O. Hohn1, K. Strohschein2, H. Krause3, R. Kurth1, C. Scheibenbogen2, N. Bannert1
    1 Robert Koch-Institute, ZBS4, Berlin, Germany
    2 Charit - Universittsmedizin Berlin, Institute for Medical
    Immunology, Berlin, Germany
    3 Charit - Universittsmedizin Berlin, Urology, Berlin, Germany

    Background: A novel gammaretrovirus named xenotropic murine leukemia
    virus-related virus (XMRV) has been recently identified and found to
    have a prevalence of 40% in prostate tumor samples from US American
    patients carrying a homozygous R462Q mutation in the RNaseL gene. More
    recently XMRV has also been found in up to 67% of US American patients
    suffering from chronic fatigue syndrome (CFS) without any correlation
    to the RNaseL genotype. The aim of our study is therefore the
    determination of the XMRV prevalence in prostate cancer cases and in
    CFS patients in Germany.

    Methods: Real-time PCR was used for RNaseL genotyping of prostate
    cancer samples. Highly sensitive nested PCR and RT-PCR approaches were
    applied for the detection of XMRV gag sequences. Using recombinant
    Gag- and Env-proteins an ELISA was developed for the detection of
    anti-XMRV antibodies in human sera samples.

    Results: 589 prostate tumor samples were genotyped by real-time PCR
    with regard to the RNaseL mutation. In agreement with earlier data,
    12.9% (76 samples) were shown to be of the QQ genotype. However, XMRV
    specific sequences were detected at neither the DNA nor the RNA level
    and none of the 146 sera analyzed from prostate cancer patients
    contained XMRV-specific antibodies. The outcome of the ongoing CFS
    study will be presented at the conference.

    Conclusion: Our results indicate a much lower prevalence (or even
    complete absence) of XMRV in prostate tumor samples in Germany. One
    possible reason for this could be a relatively recent acquisition of
    the virus from a murine host and a geographically restricted incidence
    of XMRV infections.

    ALSO

    P01
    Functional and sequence variants of the XPR1 receptor for mouse xenotropic
    gammaretroviruses

    Y. Yan1, Q. Liu1, C. Martin1, K. Wollenberg2, C.A. Kozak1
    1 National Institute of Allergy and Infectious Diseases, Laboratory of Molecular Microbiology, Bethesda MD, USA
    2 National Institute of Allergy and Infectious Diseases, Bioinformatics and Computational Biosciences Branch Office
    of Cyber Infrastructure and Computational Biology, Bethesda MD, USA

    The evolutionary interactions between retroviruses and their receptors result in the appearance of novel viral envelope variants and host restrictions on entry. The mouse xenotropic/polytropic (X/P-MuLV) gammaretroviruses rely on the XPR1 cell surface receptor for entry into host cells, and polymorphic variants of this receptor have been identified in different rodent species. We used a panel of 7 X/P-MuLVs with 6 distinct tropisms in rodent cells to screen for infectivity on cells of mammals carrying sequence variants of XPR1. The X/P-MuLVs were tested in a single round infectivity assay and included 2 X-MuLVs, 2 P-MuLVs, 2 wild mouse isolates and XMRV, an X-MuLV-like virus that has been found in human prostate cancers and patients with chronic fatigue syndrome. We identified 11 tropisms defined by resistance to different combinations of these viruses. Most resistance patterns were recapitulated in hamster or mouse cells expressing cloned XPR1 genes, and sequence comparisons and mutational analysis identified residues critical for entry.

    We also show that XPR1 is under positive selection in rodents, and that one of the two residues under strong selection is critical for virus entry. We describe the distribution of the 4 known functional variants of mouse XPR1 in Mus species and identify a novel 5th XPR1 variant that is highly restrictive and has a widespread distribution in Eurasian mice that harbor X-MuLVs. These gammaretroviruses and their XPR1 receptor are thus highly functionally polymorphic, a consequence of the evolutionary pressures that favor both host resistance and virus escape mutants. This variation accounts for multiple naturally occurring virus resistance phenotypes and perhaps contributes to the widespread distribution of these viruses in rodent and non-rodent species.
  14. Michelle

    Michelle Decennial ME/CFS patient

    Messages:
    104
    Likes:
    10
    Portland, OR
    D'oh! My spelling sucks when I've first waken up. Dr Judy's last name should end in an S not a Z. But I can't seem to edit the thread title.
  15. kurt

    kurt Senior Member

    Messages:
    1,132
    Likes:
    175
    USA.Earth
    Thanks. Someone posted this yesterday but we were asked to remove it as it was unpublished. However, given that this is from a published program available now online, I think we have to allow this. If anyone has contrary information, please contact the MODs...
  16. kurt

    kurt Senior Member

    Messages:
    1,132
    Likes:
    175
    USA.Earth
    That requires a MOD or Admin. Anyway, it is fixed now.

    Mikovits' comment about cytokine signature is interesting, hopefully more will be published on that.
  17. Hope123

    Hope123 Senior Member

    Messages:
    1,141
    Likes:
    532
    Most interesting part to me bolded. Hope someone can report back. Is this the same German group that WPI was working with? The group that found negative results intitially in prostate cancer but were willing to re-run their samples with WPI techniques?
  18. Gerwyn

    Gerwyn Guest


    THIS STUDY HAS BEEN PUBLISHED IN RETROVIROLOGY IN NOVEMBER 2009. THE BITS IN RED ARE THE ONLY ADDITION TO THE ORIGINAL PAPER.THE STUDY RE PROSTATE PATIENTS IS NOT A RERUN BUT A REPRESENTATION OF AN ALREADY PUBLISHED PAPER>THEY APPEAR TO BE CLAIMING THAT IT IS NEW BUT IT IS NOT

    Prevalence of XMRV in prostate cancer and chronic fatigue syndrome
    patients in Germany'
    O. Hohn1, K. Strohschein2, H. Krause3, R. Kurth1, C. Scheibenbogen2, N. Bannert1
    1 Robert Koch-Institute, ZBS4, Berlin, Germany
    2 Charit - Universittsmedizin Berlin, Institute for Medical
    Immunology, Berlin, Germany
    3 Charit - Universittsmedizin Berlin, Urology, Berlin, Germany

    Background: A novel gammaretrovirus named xenotropic murine leukemia
    virus-related virus (XMRV) has been recently identified and found to
    have a prevalence of 40% in prostate tumor samples from US American
    patients carrying a homozygous R462Q mutation in the RNaseL gene. More
    recently XMRV has also been found in up to 67% of US American patients
    suffering from chronic fatigue syndrome (CFS) without any correlation
    to the RNaseL genotype. The aim of our study is therefore the
    determination of the XMRV prevalence in prostate cancer cases and in
    CFS patients in Germany.


    Methods: Real-time PCR was used for RNaseL genotyping of prostate
    cancer samples. Highly sensitive nested PCR and RT-PCR approaches were
    applied for the detection of XMRV gag sequences. Using recombinant
    Gag- and Env-proteins an ELISA was developed for the detection of
    anti-XMRV antibodies in human sera samples.

    Results: 589 prostate tumor samples were genotyped by real-time PCR
    with regard to the RNaseL mutation. In agreement with earlier data,
    12.9% (76 samples) were shown to be of the QQ genotype. However, XMRV
    specific sequences were detected at neither the DNA nor the RNA level
    and none of the 146 sera analyzed from prostate cancer patients
    contained XMRV-specific antibodies. The outcome of the ongoing CFS
    study will be presented at the conference.

    Conclusion: Our results indicate a much lower prevalence (or even
    complete absence) of XMRV in prostate tumor samples in Germany. One
    possible reason for this could be a relatively recent acquisition of
    the virus from a murine host and a geographically restricted incidence
    of XMRV infections.
  19. Michelle

    Michelle Decennial ME/CFS patient

    Messages:
    104
    Likes:
    10
    Portland, OR
    Kurt:

    Ah, that explains it. I'm usually a day behind Co-Cure as I get the daily email digest. And people here are usually faster than Co-Cure. ;-)

    Thanks for changing my spelling error.

    Hope: Yes, I'm curious about that one too! Though considering their results with prostate cancer and the problems with PCR, I don't feel hopeful. :-(

    Curious about that last abstract regarding rodents, probably because that's the one I understand the least.
  20. Stone

    Stone Senior Member

    Messages:
    371
    Likes:
    6
    NC
    Since this is allowed, could the post from yesterday be replaced? It was amazing and it had some information in it I really needed for my infectious disease doctor. Whaddya say?

See more popular forum discussions.

Share This Page